Nanotope
Stage
Other Investors | AliveAbout Nanotope
Nanotope is a regenerative medicine company that leverages a core set of technologies to address multiple therapeutic markets. Nanotope is developing a suite of products, each customized to regenerate specific tissues; including neuronal, vascular, bone, myocardial, and cartilage. The products are injectable compounds that work with surviving cells in and around the point of damage to initiate and support tissue regeneration and growth. Once regeneration is complete, the compounds are safely broken down and removed by the body. Nanotope's lead products target neuron regeneration for prevention or reversal of paralysis associated with spinal cord injury and angiogenesis for wound healing and the treatment of peripheral artery disease.n
Missing: Nanotope's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Nanotope's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Nanotope
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Nanotope is included in 1 Expert Collection, including Regenerative Medicine.
Regenerative Medicine
1,818 items
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
Nanotope Patents
Nanotope has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/16/2008 | 12/13/2011 | Tissue engineering, Biomaterials, Food additives, Polymers, Molecular biology | Grant |
Application Date | 4/16/2008 |
|---|---|
Grant Date | 12/13/2011 |
Title | |
Related Topics | Tissue engineering, Biomaterials, Food additives, Polymers, Molecular biology |
Status | Grant |
Nanotope Frequently Asked Questions (FAQ)
Where is Nanotope's headquarters?
Nanotope's headquarters is located at 8025 Lamon Avenue, Suite 450, Aurora.
What is Nanotope's latest funding round?
Nanotope's latest funding round is Other Investors.
Who are the investors of Nanotope?
Investors of Nanotope include Fitzsimons Colorado Science and Technology Park.
Who are Nanotope's competitors?
Competitors of Nanotope include OcuNexus Therapeutics, Histogen, Histogenics, Regentis Biomaterials, Juventas Therapeutics, FirstString Research, Synapsin Pharmaceuticals, BioMimetic Therapeutics, VeloMedix, Harvest Technology and 17 more.
Compare Nanotope to Competitors
Biofisica develops and markets products for soft tissue wound healing and tissue regeneration based on an exclusive and technology that uses electrical stimulation and hydro-gel materials.
FirstString is a biopharmaceutical company dedicated to discovering therapies for inflammation-based medical conditions.
OcuNexus Therapeutics is a development stage biopharmaceutical company that develops treatments for front- and back-of-the-eye diseases and disorders.
CartiCure is a MedTech company for tissue engineering; developing innovating technology for cartilage repair. CartiCure's technological platform generates original hyaline cartilage-producing cells to be transplanted into damaged joints; efficiently replenishing small and large lesions in the articular cartilage.nCarticure was established in 2005 and is currently based on the premises of the NGT High-Tech Incubator in Nazareth, Israel; all scientific work as well as on-going animal trials are being conducted at the Faculty of Medicine at Technion-Israel Institute of Technology in Haifa, Israel.
Isolating diverse creatures including species indegenous to rainforests in Malaysia, exploring new compounds which lead development of new medicine conforming to CBD and building a predominant bio-resource collection, NGS will contribute to health and progress of bioindustries in international community.
Regentis Biomaterials is focused on developing and commercializing hydrogels for tissue regeneration. The Gelrin hydrogel platform is a matrix of polyethylene glycol diacrylate (PEG-DA) and denatured fibrinogen, combining the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications. The company's flagship product, GelrinC, for the treatment of articular cartilage lesions, is currently in clinical trials.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.